Subscribe

Web Exclusives

Identification, characterization, and management of osteolytic bone lesions are key aspects of care in multiple myeloma.
Multiple myeloma (MM) is among the most challenging cancers to treat. Patients diagnosed with this disease are typically older, with a mean age of 62 years for men and 61 years for women.1 This older, often elderly population is prone to several factors that complicate treatment, including comorbid conditions, decreased physiologic reserve, cognitive and other psychosocial problems, and a greater risk for adverse drug reactions.2,3
Recent clinical evidence supports new strategies for the management of patients with relapsed and refractory multiple myeloma (MM), including the use of both approved and investigational targeted agents, new dosing regimens for established therapies, and refined, individualized sequencing plans. These approaches have the potential to benefit both clinicians and payers who strive to enhance outcomes and provide value-based care in the relapsed/refractory setting.
To determine the value of treatments for multiple myeloma (MM), healthcare professionals must evaluate supporting clinical evidence.
Over the past 20 years, research in multiple myeloma (MM) has delineated the molecular and genetic mechanisms of the disease.
Over the past 2 decades, the standard of care for multiple myeloma (MM) has shifted with the introduction of novel, targeted agents such as bortezomib, lenalidomide, and thalidomide.
The treatment of multiple myeloma (MM) is advancing to the point where it is becoming a chronic disease.
he therapeutic paradigm for multiple myeloma (MM) continues to evolve, due to advances in our understanding of the molecular and genetic basis of the disease.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.
Page 4 of 6
Results 31 - 40 of 52
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology